𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations

✍ Scribed by Mette C. Ørngreen; Morten Dunø; Rasmus Ejstrup; Ernst Christensen; Marianne Schwartz; Massimo Sacchetti; John Vissing

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
105 KB
Volume
57
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Patients with the myopathic form of carnitine palmitoyltransferase II (CPT II) deficiency typically experience muscle pain, cramps, and myoglobinuria during prolonged exercise. It has been suggested that carriers of CPT2 gene mutations also may have milder clinical symptoms, but fatty acid oxidation (FAO) has never been investigated in vivo in this group. We studied fuel utilization by indirect calorimetry and stable isotope methodology in four patients with CPT II deficiency, three subjects who carried one CPT2 gene mutation, and five healthy control subjects. Cycle exercise at a constant workload of 50% of maximal oxygen uptake capacity was used to facilitate FAO. We found that in vivo oxidation of long‐chain fatty acids was normal at rest but severely impaired during prolonged, low‐intensity exercise in patients with CPT II deficiency, and that two of the single CPT2 gene mutation carriers, who displayed symptoms of CPT II deficiency, had an FAO comparable with the patients. These results indicate that residual CPT II activity is sufficient to maintain long‐chain FAO at rest in CPT II deficiency but not to increase FAO during exercise. The findings also suggest that single CPT2 gene mutations may exert a dominant‐negative effect on the tetrameric CPT II protein. Ann Neurol 2005;57:60–66

📜 SIMILAR VOLUMES

A missense mutation in the OCTN2 gene as
A missense mutation in the OCTN2 gene associated with residual carnitine transport activity
✍ Yuhuan Wang; Michelle A. Kelly; Tina M. Cowan; Nicola Longo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 302 KB 👁 1 views

Primary carnitine deficiency is an autosomal recessive disorder of fatty acid oxidation caused by defective carnitine transport. This disease can present early in life with hypoketotic hypoglycemia and acute metabolic decompensation, or later in life with skeletal or cardiac myopathy. Mutations abol

Two CPT2 mutations in three Japanese pat
Two CPT2 mutations in three Japanese patients with carnitine palmitoyltransferase II deficiency: Functional analysis and association with polymorphic haplotypes and two clinical phenotypes
✍ Kaoru Wataya; Jun Akanuma; Patrizia Cavadini; Yoko Aoki; Shigeo Kure; Federica I 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 2 views

## Carnitine palmitoyltransferase II (CPT II) deficiency manifests as two different clinical phenotypes: a muscular form and a hepatic form. We have investigated three nonconsanguineous Japanese patients with CPT II deficiency. Molecular analysis revealed two missense mutations, a glutamate (174)to

Two novel missense mutations of the OCTN
Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency
✍ E. Mayatepek; J. Nezu; I. Tamai; A. Oku; M. Katsura; M. Shimane; A. Tsuji 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 20 KB 👁 1 views

Primary systemic carnitine deficiency (SCD) is an autosomal recessive disorder of fatty acid oxidation caused by defective cellular carnitine transport. The disease is characterized by metabolic derangement simulating Reye´s syndrome, hypoglcaemia, progressive cardiomyopathy and skeletal myopathy. R